Table 1.
Clinical features of 16 patients with MPM
| ID | Age/Sex | Histology | BMAL1 Status (IHC score) |
Asbestos exposure |
OS (M) | Staging |
Surgery | Therapy | |
|---|---|---|---|---|---|---|---|---|---|
| Clinical | Pathological | ||||||||
| 1 | 50/M | Biphasic | Negative (1+) | + | 2.5 | T2N0M0/II | T3N2M0/III | Right EPP | No |
| 2 | 54/M | Biphasic | Negative (1+) | + | 24.0 | T2N0M0/II | T2N0M0/II | Left EPP | No |
| 3 | 56/M | Epithelioid | Negative (1+) | + | 25.3 | T3N2M0/III | T4N0M0/IV | Left EPP | No |
| 4 | 65/M | Epithelioid | Negative (0) | + | 8.8 | T3N1M0/III | T3N2M0/III | Right EPP | Neoadjuvant CT |
| 5 | 46/F | Epithelioid | Negative (1+) | − | 36.0 | T1bN0M0/Ib | T3N2M0/III | Left EPP | Adjuvant CT + LRT |
| 6 | 70/F | Epithelioid | Negative (0) | − | 27.6 | T1bN1M0/III | T2N1M0/III | Left EPP | Neoadjuvant CT |
| 7 | 65/M | Epithelioid | Positive (3+) | + | 8.4 | T3N0M0/III | T4N0M0/IV | Right EPP | Neoadjuvant CT |
| 8 | 60/M | Biphasic | Negative (0) | + | 31.3 | T3N2M0/III | T3N0M0/III | Right EPP | Neoadjuvant CT + PHR |
| 9 | 62/M | Epithelioid | Positive (2+) | + | 13.0 | T3N0M0/III | T4NxM0/IV | Left pleurectomy | Neoadjuvant CT |
| 10 | 67/M | Biphasic | Negative (1+) | − | 11.6 | T2N1M0/III | T3N0M0/III | Right EPP | Neoadjuvant CT + PHR |
| 11 | 66/M | Biphasic | Negative (0) | + | 8.3 | T2N0M0/II | T3N0M0/III | Right EPP | Neoadjuvant CT |
| 12 | 67/M | Epithelioid | Positive (2+) | + | 3.6 | T2N0M0/II | T3N2M0/III | Right EPP | No |
| 13 | 68/M | Epithelioid | Positive (3+) | − | 7.7 | T3N0M0/III | T3N0M0/III | Left EPP | Neoadjuvant CT + PHR |
| 14 | 63/M | Epithelioid | Positive (3+) | + | 1.9 | T2N0M0/II | T3N0M0/III | Lt EPP | Neoadjuvant CT |
| 15 | 68/M | Sarcomatoid | Negative (0) | + | 1.0 | T3N2M0/III | T3N0M0/III | Right EPP | Neoadjuvant CT |
| 16 | 64/M | Epithelioid | Negative (1+) | + | 0.8 | T2N0M0/II | T3N2M0/III | Left EPP | Neoadjuvant CT |
Abbreviations: Id, patient’s number; IHC, immunohistochemical score for BMAL1; OS, overall survival; M, month; EPP, extra-pleural pneumonectomy; neoadjuvant CT, neoadjuvant chemotherapy (cisplatin + pemetrexed); adjuvant chemotherapy (cisplatin + pemetrexed); LRT, local radiation therapy; PHR, post-operative hemithoracic radiation.